2141P - Symptom burden and health-related quality of life (HRQoL) in platinum-resistant or -refractory ovarian cancer (PROC): A systematic literature review (SLR)

Background

PROC is characterized by a cumulative burden of progressive disease and prior treatments. The goals of treatment are symptom reduction, HRQoL improvement or stabilization, and providing survival benefits with limited toxicity. We aimed to comprehensively characterize HRQoL in patients with PROC.

Methods

An SLR was conducted per Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. MEDLINE®, Embase®, EconLit, Cochrane, and relevant conference proceedings were searched for randomized and non-randomized studies reporting HRQoL in patients with advanced ovarian cancer and disease recurrence within 6 months of platinum-based chemotherapy published January 2010–March 2, 2023.

Results

Of 13,043 records identified in the SLR, 39 were included. The most common HRQoL measures were European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30 (n=28), EORTC QLQ-Ovarian Cancer Module (OV28) (n=23), Functional Assessment of Cancer Therapy (FACT)-Ovarian (n=10), and FACT Ovarian Symptom Index (FOSI) (n=6). Gastrointestinal (GI) problems, fatigue, sleep disturbances, pain, anxiety, and depression were commonly reported at baseline. HRQoL scores and outcomes were heterogeneous, however, across studies and treatments, the majority of patients experienced stable or worsening HRQoL. Few studies reported clinically meaningful improvements in HRQoL in abdominal/GI symptoms, pain, insomnia, global health, function (physical, emotional, role, social), and these occurred in less than half of patients. Worsening of dyspnea, GI symptoms, chemotherapy side effects, and peripheral neuropathy were noted with some treatments including pegylated liposomal doxorubicin.

Conclusions

Disease-specific and generic HRQoL instruments demonstrated a substantial burden including GI disturbances, pain, fatigue, emotional distress, and poor functioning in PROC. Existing treatments provided no HRQoL improvement for the majority of patients. A substantial unmet need remains for tolerable treatments that reduce symptoms and improve HRQoL among patients with PROC.

Clinical trial identification

Legal entity responsible for the study

Novocure.

Funding

Novocure.

Disclosure

N. Indukuri, M. Payer: Financial Interests, Personal, Full or part-time Employment: Novocure; Financial Interests, Personal, Stocks/Shares: Novocure. Z. Chen: Financial Interests, Personal, Full or part-time Employment: Cytel Inc.; Financial Interests, Personal, Stocks/Shares: Cytel Inc.